Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal

References

• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100–1104.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009;124:1497–1502.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34:322–331.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753–1757.
   PubMed Web of Science ®Google Scholar
• Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497–502.
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307–311.
   PubMed Web of Science ®Google Scholar
• Hsiao SC, Ichinohasama R, Lin SH, et al. EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract 2009;205:43–49.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692–701.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014;(6):Cd000957.
   PubMed Web of Science ®Google Scholar
• Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691–702.
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Gestermann N, Amiel C, et al. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 2009;11:R77.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Guis S, Meynard JB, et al. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:762–767.
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943–1949.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 2010;101:1309–1313.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106–1109.
   PubMed Web of Science ®Google Scholar
• Ozsan N, Cagirgan S, Saydam G, et al. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey. Pathol Res Pract 2013;209:471–478.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Hakoda M, Yamanaka H, et al. Methotrexate (MTX) induces apoptosis in activated T cells. Arthritis Rheum 1995;38(Suppl.1):S192.
   Google Scholar
• Fairbanks LD, Ruckemann K, Qiu Y, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999;342:143–152.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167–175.
   PubMed Web of Science ®Google Scholar
• O’Meara A, Headon B, Reen DJ. Effect of methotrexate on the immune response in children with acute lymphatic leukaemia. Immunopharmacology 1985;9:33–38.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002;16:1311–1318.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001;28:865–871.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Rajnai H, Heyning FH, Koens L, et al. The density of CD8 + T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. Virchows Arch 2014;464:229–239.
   PubMed Web of Science ®Google Scholar
• Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8 + lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 2013;109:2705–2713.
   PubMed Web of Science ®Google Scholar
• Bachmayr-Heyda A, Aust S, Heinze G, et al. Prognostic impact of tumor infiltrating CD8 + T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer 2013;13:422.
   PubMed Web of Science ®Google Scholar
• Tsuchikawa T, Ikeda H, Cho Y, et al. Association of CD8 + T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol 2011;164:50–56.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Desire N, Rozenbaum W, et al. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J Clin Microbiol 2000;38:1404–1408.
   PubMed Web of Science ®Google Scholar
• Tedeschi R, Enbom M, Bidoli E, et al. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001;39: 4269–4273.
   PubMed Web of Science ®Google Scholar
• Polstra AM, van den Burg R, Goudsmit J, et al. Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma. J Clin Microbiol 2003;41: 5488–5491.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Nasr R, El-Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000;14: 716–721.
   PubMed Web of Science ®Google Scholar
• Kinpara S, Kijiyama M, Takamori A, et al. Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 2013;10:52.
   PubMed Web of Science ®Google Scholar
• Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648–653.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):Cd008794.
   Web of Science ®Google Scholar